References
- Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al.. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.
- Simmons DL. Anti-adhesion therapies. Curr Opin Pharmacol. 2005;5(4):398–404.
- Holmen C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, et al.. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011;17(6):708–19.
- Merelli E, Casoni F. Prognostic factors in multiple sclerosis: role of intercurrent infections and vaccinations against influenza and hepatitis B. Neurol Sci. 2000;21(4 Suppl 2):S853–6.
- Salemi S, D’Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol. 2010;29(3):270–314.
- van den Berg R, van Hoogstraten I, van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev. 2009;11(3):157–64.
- Michiels B, Govaerts F, Remmen R, Vermeire E, Coenen S. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine. 2011;29(49):9159–70.
- Sundstrom P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nystrom L, et al.. An altered immune response to Epstein–Barr virus in multiple sclerosis: a prospective study. Neurology. 2004;62(12):2277–82.
- Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24(8):1159–69.
- Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine. 2008;26(29–30):3551–5.